Travere Therapeutics, Inc. (TVTX)

In May 2025, Travere Therapeutics reported its Q1 numbers, with revenues rising year-over-year, but the stock dropped due to the FDA adding an advisory committee meeting for FILSPARI in FSGS. In October 2025, FILSPARI was recognized in clinical practice guidelines, and the FDA did not require an Advisory Committee meeting for FILSPARI in FSGS, leading to the stock hitting a new 52-week high. A Phase 4 clinical study (SPARX) evaluating sparsentan in post-transplant IgAN or FSGS began in October 2025. Travere Therapeutics is scheduled to release its Q3 2025 financial results on October 30, 2025.

There is no specific information indicating significant demand seasonality for Travere Therapeutics' products and services. The market for rare kidney diseases is generally experiencing growth, suggesting a consistent and growing demand rather than seasonal fluctuations for its therapies.

Travere Therapeutics, Inc. is a biopharmaceutical company focused on identifying, developing, and delivering therapies for individuals with rare kidney and metabolic diseases. The company's major products include Filspari (sparsentan) for IgA Nephropathy (IgAN) and Focal Segmental Glomerulosclerosis (FSGS), Thiola and Thiola EC (tiopronin tablets) for cystinuria, and Pegtibatinase (TVT-058) for classical homocystinuria (HCU). The company is also engaged in identifying potential small molecule therapeutics for Alagille syndrome (ALGS).

Travere Therapeutics primarily operates in the United States and Ireland. Its shareholder base is geographically diverse, including institutional investors from the United States, United Kingdom, Switzerland, Luxembourg, Canada, France, Germany, Israel, Ireland, Norway, Hong Kong, Puerto Rico, China, United Arab Emirates, Sweden, and the Netherlands.

Travere Therapeutics has maintained its brand reputation as a developer of rare disease therapies through scientific rigor, clinical transparency, and collaboration with the rare disease community. The FDA approval of FILSPARI for IgA nephropathy and its recognition in clinical practice guidelines positively impacted its reputation. Streamlined communication with regulatory authorities regarding FILSPARI's supplemental new drug application for FSGS also reflects positively on its regulatory efficiency.

Travere Therapeutics has significant institutional ownership, including Janus Henderson Group Plc, Armistice Capital, Llc, BlackRock, Inc., Vanguard Group Inc, Macquarie Group Ltd, State Street Corp, Adage Capital Partners Gp, L.l.c., Renaissance Technologies Llc, Perceptive Life Sciences Master Fund, Ltd., and Emerald Advisers, LLC. The largest individual shareholder is Ruth Shepley, who owns 49.00 million shares, representing 54.97% of the company.